



Hi-Affi™ Human Anti-Human LAG3 Monoclonal antibody, clone Favezelimab (DMAB-CDB25921)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Favezelimab. Favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand.
Specificity	Favezelimab binds to the D1 domain of human LAG3.
Target	Human LAG3
Immunogen	Human LAG3
Isotype	IgG
Source/Host	Human
Species Reactivity	Human
Clone	Favezelimab
Purification	>90% determined by SDS-PAGE
Conjugate	Unconjugated
Applications	Suitable for use in Crystallography, EM. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid

Concentration	lot specific
Size	200 µg, 1 mg
Buffer	PBS (endotoxin < 1EU/mg, lower endotoxin levels may also be offered upon request)
Preservative	None
Storage	Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles.
Ship	Dry ice

BACKGROUND

Introduction	LAG-3 is a 70-kDa surface glycoprotein belonging to the Ig superfamily with homology to CD4. LAG-3 binds to MHC class II with higher affinity than CD4 and is thought to be involved in the negative regulation of T cell activation and homeostatic proliferation. Surface expression of LAG-3 has been reported on activated T cells (including regulatory T cells) and NK cells. CD8+ T cells usually express LAG-3 at significantly higher levels than CD4+ T cells. Coexpression of LAG-3 and CD49b has been proposed to identify human and mouse Type 1 regulatory T cells (Tr1 cells).
Keywords	CD223; LAG3; LAG-3; lymphocyte activation gene 3